In tumor vaccination, the presentation of tumor antigens allows effective activation of tumor-specific T-cells (i.e., CD8+ cytotoxic T-cells), thereby inducing or increasing an antitumor immune response. The gene discussed is CD8A; the disease is neoplasm.